Bevifimod Biosimilar – Research Grade from ProteoGenix; catalogue PX-TA2531; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Bevifimod Biosimilar – Research Grade is a recombinant research-use protein designed for studies involving immune modulation, B-cell biology, macrophage activity, and antibody-mediated immune mechanisms. As a biosimilar of bevifimod, also known as PRTX-100, this product supports researchers investigating the biological activity of Staphylococcal protein A and its interaction with immune cell populations involved in inflammatory and autoimmune pathways.
Bevifimod is associated with the selective modulation of immune responses through binding to VH3 immunoglobulin-expressing B cells and macrophage or monocyte populations. This interaction makes it a relevant research target for studying B-cell activation, antibody-mediated signaling, immune complex biology, and macrophage-driven effector functions.
By engaging immune cells involved in pathogenic antibody responses, bevifimod is commonly studied in experimental models exploring immune regulation, inflammatory signaling, and mechanisms linked to autoimmune disease biology.
Bevifimod Biosimilar – Research Grade is suitable for in vitro and preclinical research applications focused on immune cell modulation and antibody-related mechanisms. It may be used to support studies in autoimmune disease research, immune thrombocytopenia research, rheumatoid arthritis-related models, B-cell response analysis, and macrophage or monocyte functional assays.
This product can also be used as a reference protein or research reagent for assay development, target validation, comparative biosimilar studies, and screening workflows involving immune-mediated inflammation.
Researchers may use Bevifimod Biosimilar – Research Grade in PBMC-based assays, B-cell activation studies, monocyte or macrophage response assays, and antibody-mediated phagocytosis models. It is also relevant for investigating VH3-related immunoglobulin interactions, immune signaling modulation, and cellular mechanisms involved in platelet destruction or inflammatory immune responses.
Its research-grade format makes it a practical tool for laboratories evaluating bevifimod-related biology, developing immune-focused assays, or comparing protein activity in controlled experimental settings.
Bevifimod Biosimilar – Research Grade is intended exclusively for research applications. It is not intended for diagnostic, clinical, or therapeutic use.
ProteoGenix catalogue number PX-TA2531.
Target: Bevifimod Biosimilar – Research Grade; Host: Mammalian cells; Clonality: Monoclonal antibody; Expression system: Mammalian; Purity: >95% as determined by SDS-PAGE.; Buffer: 0.01M PBS pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
